Absite Reviewreview RTC 1/22/10 Topicstopics

Absite Reviewreview RTC 1/22/10 Topicstopics

AbsiteAbsite ReviewReview RTC 1/22/10 TopicsTopics CoverCover HighlightsHighlights ofof thethe following:following: •• GastrointestinalGastrointestinal HormonesHormones •• TransplantTransplant (rejection,(rejection, medicationsmedications)) •• HematologyHematology GiGi HormonesHormones • Gastrin • Origin: G cells in antrum • Target: parietal and chief cells • Action: ×HCl, intrinsic factor, pepsinogen secretion • Stimulators: AA’s, vagal input, antral distension, pH>3 • Inhibitors: secretin/CCK, somatostatin, pH<3, VIP, GIP • Omeprazole blocks H/K ATPase of parietal cell •• AcetylcholineAcetylcholine andand HistamineHistamine causecause HClHCl secretionsecretion GIGI hormoneshormones • Somatostatin “the great inhibitor” • Origin: D cell in antrum • Target: many cells in GI tract • Action: inhibits release of gastrin and HCl, insulin, glucagon, secretin; decreases biliary and pancreatic output. • Stimulator: acid in duodenum • Octreotide (somatostatin analogue) GIGI hormoneshormones • Cholecystokinin • Origin: I cells of duodenum and jejunum • Action: ×gallbladder contraction, sphincter of Oddi relaxation, ×pancreatic enzyme secretion and intestinal motility. • Stimulators: amino acids and fatty acids GiGi hormoneshormones • Secretin • Origin: S cells of duodenum • Action: ×pancreatic HCO3 release, bile flow; inhibits gastrin and HCl release • Stimulators: fatty acids, bile, pH<4.0 • Inhibitors: pH>4.0 and gastrin QuestionsQuestions • Which of the following statements are true or false? • Reducing vagal input will result in higher gastric pH and reduced HCl. • TRUE • Rising pH levels in the duodenum stimulate secretion of somatostatin. • FALSE • Amino acids cause increased release of cholecystokinin and secretin. • TRUE • Secretin stimulates biliary and pancreatic flow, and increases gastrin release from the antrum. • FALSE GiGi hormoneshormones • Insulin • Origin: beta cells in pancreas • Action: cellular glucose uptake; ×protein synthesis • Stimulators: glucose, glucagons, CCK • Inhibitors: somatostatin, pancreatostatin GiGi hormoneshormones • Glucagon • Origin: alpha cells of pancreas • Action: glycogenolysis, gluconeogenesis, lipolysis, ketogenesis, Ð gastric acid and pancreatic secretion, ÐGI motility and MMC’s • Stimulators: Ðglucose, Ïamino acids, acetylcholine, and gastrin -releasing peptide • Inhibitors: Ïglucose and insulin; somatostatin • Treatment for beta blockade overdose GiGi hormoneshormones • Gastric Inhibitory Peptide • Origin: K cells in duodenum • Target: parietal cells in stomach and beta cells • Action: ÐHCl secretion and pepsin; Ï insulin release • Stimulators: amino acids, glucose, long -chain FA’s, and ÐpH GiGi hormoneshormones • Vasoactive Intestinal Peptide (VIP) • Origin: various cells in GI tract and pancreas • Action: Ïintestinal secretion (water, electrolytes) and motility • Stimulators: fatty acids, acetylcholine • Pancreatic Polypetide • Origin: Islet cells in pancreas • Action: Ðpancreatic and gallbladder secretion • Stimulators: food, vagal stimulation GiGi hormoneshormones • Motilin • Origin: various intestinal cells • Action: Ïsmall bowel motility • Stimulators: duodenal acid, food, vagal input • Inhibitors: somatostatin, secretin, pancreatic polypeptide • Erythromycin acts on this receptor GiGi hormoneshormones • Bombesin (gastrin-releasing peptide) • Ïgastric acid secretion, Ïpancreatic secretion, Ïmotility • Peptide YY • Released from TI after fatty meal • Inhibits acid secretion, pancreatic and gallbladder secretion QuestionsQuestions • Which of the following questions are true or false? • GIP is released from the duodenum in the presence of • GIP is released from the duodenum in the presence of glucose, AA’s, long-chain fatty acids, and low pH. • TRUE • Glucagon and Peptide YY both decrease GI motility and pancreatic secretion • TRUE • VIP causes decreased GI motility and decreased absorption. • FALSE • Bombesin results in increased GI motility • TRUE • Pancreatic polypeptide stimulates release of pancreatic enzymes. • FALSE TransplantTransplant MedsMeds • Azathioprine (Imuran) • Inhibits purine synthesis affecting T cells • 6-mercaptopurine is active metabolite • Side effects: myelosuppression • Common maintenance for renal tx pts • Mycophenolate (Cellcept) • Similar in function to Azathioprine • Side effets: GI intolerance • Steroids • Inhibit genes for cytokine synthesis (IL-1, 6) and macrophages • Side effects: adrenal suppression, osteoporsis, hyperglycemia, weight gain, etc. TransplantTransplant medsmeds • Cyclosporin • Binds cyclosporin protein inhibiting genes for cytokine synthesis (IL- 2,3,4 and INF-gamma) 2,3,4 and INF-gamma) • Side effects: nephrotoxicity, hepatotoxicity, HUS, seizures, gingival hyperplasia hyperplasia • Hepatic metabolism and biliary excretion • Many drug interactions • FK-506 (Prograf) • Binds FK binding protein; action similar to cyclosporin • Side effects: nephrotoxicity, neurologic and mood changes, HTN TransplantTransplant medsmeds • ATGAM • Equine polyclonal antibodies against T cells (CD2,3,4,8) • Used for induction therapy • Complement dependent • Thymoglobulin • Rabbit polyclonal antibodies • Action similar to ATGAM • Often used for induction of immunosuppression • OKT3 • Monoclonal antibodies that block antigen recognition function of T cells by binding CD3 • Used for severe rejection QestionsQestions • All of the following are true regarding Azathioprine except: • 6-mercaptopurine is the active metabolite • The key mechanism is to inhibit genes which regulate cytokine synthesis in T cells cytokine synthesis in T cells • Routine CBC’s are necessary while taking this medication medication • This drug is used for maintenance immunosuppression QuestionsQuestions • Which of the following are true or false? • OKT3 is a monoclonal antibody used for severe rejection • OKT3 is a monoclonal antibody used for severe rejection • TRUE • FK -506 effectively inhibits nucleotide synthesis similar to Azathioprine • FALSE • Thymoglobulin is a polyclonal antibody made from rabbits often used for induction therapy • TRUE • Nephrotoxicity, hepatotoxicity, and neurologic changes are all common side effects of cyclosporin. • TRUE rejectionrejection RejectionRejection • Hypercute Rejection • Occurs within minutes to hours • Caused by preformed antibodies • Results in complement cascade and vessel thrombosis • Need immediate retransplant • Accelerated Rejection • Occurs < 1 week • Caused by sensitized T cells to donor antigens • Results in secondary immune response • Tx: increase immunosuppression with pulse steroids, possibly OKT3 OKT3 rejectionrejection • Acute Rejection • Occurs within 1 week to 1 month • Caused by T cells (cytotoxic and Helper T) • Tx: increase immunosuppression, pulse steroids, possibly OKT3 OKT3 • Chronic Rejection • Partly a Type IV hypersensitivity reaction • Leads to inevitable graft fibrosis and vascular injury • Tx: increase existing immunosuppression – no cure questionsquestions • True or False: • Pulse steroids and OKT3 are used for acute rejection. • TRUE • Hyperacute rejection is secondary to sensitized T cells against donor antigens. against donor antigens. • FALSE • Chronic rejection manifests in graft thrombosis and vascular injury vascular injury • TRUE QuestionsQuestions • After receiving a renal transplant, a patient is started on a regimen of tacrolimus, corticosteroids, mycophenolate mofetil, and trimethoprim-sulfa. Two weeks after transplant, she develops seizures. The most likely cause of these symptoms is: • Tacrolimus toxicity • Corticosteroid toxicity • Mycophenolic acid toxicity • Rejection • Meningitis questionsquestions • Which of the following statements about acute rejection is NOT true? • It is T-cell mediated • It is related to organ-host human leukocyte antigen disparity • Treatment can save the grafted organ in 90% to 95% of cases • It does not occur with living related donors. • It is associated with an increased risk of chronic rejection HematologyHematology hematologyhematology • Coagulation • All factors made in liver except VIII (endothelium) • Vitamin K-dependent factors: • II, VII, IX, X, protein C and S • Prostacyclin (PGI2): • From endothelium • Decreases platelet aggregation, causes vasodilation • Thromboxane (TXA2): • From platelets • Causes platelet aggregation and vasoconstriction hematologyhematology • Von Willebrand’s disease • Most common congenital disorder • Type 1 and 2 autosomal dominant; 3 recessive • vWF links Gp1b receptor on platelet to collagen • PT normal; PTT normal or high • Have long bleeding time (ristocetin test) • Type 1 and 3 from reduced quantity • Treat with cryo, DDAVP • Type 2 is defect in vWF function • Treat with cryo hematologyhematology • Cryoprecipitate • Highest concentration of vWF and VIII • Used in von Willebrands disease (especially type 2) and Hemophilia A Hemophilia A • FFP • Contains all factors including protein C, S, and AT3 • DDAVP • Cause release of VIII and vWF from endothelium • Only effective in vWF type 1 and 3 hematologyhematology • Platelet disorders • Clinical Signs: bruising, epistaxis, petechiae, purpura • Acquired thromocytopenia: heparin, H2 blockers • Glanzmann ’s thrombocytopenia: • GpIIb/IIIa receptor deficiency on platelets (can’t bind to each other through fibrin) • Tx: platelets • Bernard Soulier • GpIb receptor deficiency (can’t bind collagen - vWF) • Tx: platelets hematologyhematology • Hypercoagulability (virchow’s triad) • Leiden factor: • 30% of spontaneous DVT’s • Most common congenital hypercoagulability • Factor V resistant to degredation

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    34 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us